|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to characterize the mechanisms of resistance to lorlatinib occurring in patients with <i>ALK</i>-rearranged lung cancer and design new therapeutic strategies in this setting.
|
31585938 |
2020 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
|
31562206 |
2020 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article reviewed the clinical significance and drug resistance mechanism of ALK rearrangement in lung cancer.
|
31559892 |
2020 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a blinded study, we detected ALK fusion from formalin-fixed paraffin-embedded lung cancer samples with a 100% 47) and genotyping /47) and genotyping (7/7).
|
31641223 |
2020 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of serum tumor markers (STMs) in the modern management of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung cancer remains poorly described.
|
31707279 |
2020 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
|
31390053 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACKGROUND An extensive body of research reveals the clinical value of serum tumor markers in lung cancer patients, including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), cytokeratin-19 fragments (Cyfra21-1), and neuron-specific enolase (NSE), but little is known about the clinical properties of these serum tumor markers in anaplastic lymphoma kinase (ALK)-positive lung cancer patients.
|
30673691 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The discovery of the EML4-ALK fusion kinase in 2007 was a breakthrough for this situation, and kinase fusion genes now form a group of relevant targetable oncogenes in lung cancer.
|
30941048 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.
|
30066208 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The coexistence of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement in patients with multifocal lung adenocarcinomas (LUAC) constitutes a rare molecular subtype of lung cancer.
|
31138506 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
|
30171175 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that PCR-based target sequencing using a tiling primer set and two-step mapping/alignment quantitatively detected ALK fusions in cfDNA from lung cancer patients.
|
31513617 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The second-generation ALK tyrosine kinase inhibitor brigatinib has recently been approved in the European Union for use after crizotinib treatment in patients with EML4-ALK-rearranged lung cancer.
|
31305295 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crizotinib (tyrosine kinase inhibitor) has been considered as the standard of care for advanced ALK-positive lung cancer but it only gives a median progression-free survival of 7.7-11 months.
|
31023173 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Introduction</b>: Brigatinib is a second-line inhibitor for the treatment of rearranged anaplastic lymphoma kinase (ALK) in lung cancer patients which has significant activity against brain metastases.
|
31328968 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in epidermal growth factor receptor (<i>EGFR</i>), and rearrangements of anaplastic lymphoma kinase (<i>ALK</i>) are targetable in lung cancer, while <i>BRAF</i> mutations have been successfully targeted in metastatic melanoma.
|
30886831 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: These findings show that dual inhibition of HDAC and ALK receptor tyrosine kinase activities provides a means to circumvent crizotinib resistance in lung cancer.
|
30737231 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lung cancer outcomes in NZ may be improved by providing national guidelines and funding policy for ALK testing and access to subsidized ALK TKI therapy.This article is protected by copyright.All rights reserved.
|
31318119 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a case of a patient with ALK-rearranged lung cancer progressing on three-lines of ALK-targeted therapies, with development of acquired resistance to lorlatinib, with both transformation to a neuroendocrine carcinoma, and acquisition of ALK 1196 M.
|
31319969 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this is the first report to suggest an association between cancer stem-like cells and histological transformation in ALK rearrangement-positive lung cancer.
|
30900377 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.
|
30669647 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This underscores the utility of sequential TRK inhibitor use in select patients, a paradigm that parallels the use of targeted therapies in other oncogenic driver-positive cancers, such as ALK fusion-positive lung cancers.
|
31738426 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
|
31374369 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main aim of this review is to assemble on the efficacy of alectinib for the treatment of ALK+ NSCLC, to elaborate the activity of the drug in the central nervous system, and to debate on which is the position of this compound in the treatment course of ALK+ lung cancer patients.
|
31354290 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present the PET/CT findings of extensive disseminated genital herpes simplex virus infection in a 29-year-old woman known with disseminated anaplastic lymphoma kinase-mutated nonsmall lung cancer.
|
30829864 |
2019 |